Opinion|Videos|January 14, 2025
Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up
Author(s)Max Kates, MD
Max Kates, MD, discusses how early complete response rates exceeding 50% at 3 months with newer therapies are encouraging, though long-term follow-up remains critical for evaluating durability of response and establishing real-world effectiveness compared with clinical trial outcomes.
Advertisement
Episodes in this series
- Data for newer therapies have shown that more than 50% of patients with BCG-unresponsive NMIBC experience a complete response after just 3 months of treatment. What are your thoughts on these findings?
- How do these clinical trial outcomes compare to what you see in your clinical practice when treating patients with newer therapies?
- Discuss the importance of long-term follow-up for patients receiving these newer treatments.
- What is your experience in terms of durability of response?
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
Patient Selection and Partnership in Prostate Radiotherapy Spacing
3
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
4
Alternative BCG strains may help address ongoing supply challenges in NMIBC
5